Company Overview and News


Add TIG
to your dashboard

Headline News

Bone Therapeutics: Deeply Undervalued Early Stage Biotech

2017-10-31 seekingalpha
A shot on three multibillion-dollar markets with highly unmet medical needs and very little competition (in two of the three markets). (24-3)

Rigel Pharmaceutical: An Update

2017-10-09 seekingalpha
Even with an FDA approval, I have doubts about its sales, due to two existing approved drugs. (42-3)

Grifols SA opens position in TGXSF / Tigenix Sa - Fintel.io

2017-07-13 fintel.io
July 13, 2017 - Grifols SA has filed a SC 13G form disclosing ownership of 41,929,954 shares of Tigenix Sa (OTC:TGXSF) corresponding to 16.1 percent ownership .

TiGenix Begins Recruiting for New U.S. HQ in Massachusetts

2017-06-29 biospace
Leuven (BELGIUM) - June 29, 2017, 11:30h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces it has opened an U.S. office in Cambridge, Massachusetts. Establishing U.S. operations is a significant step for TiGenix and will support its strategic goal of developing and commercializing its lead product, Cx601, for the treatment of complex perianal fistulas in Crohn's disease patients, in the United States.

TiGenix: This Stem Cell Pioneer Is Up 40% Since IPO With More Upside To Come

2017-06-27 seekingalpha
The biotech has signed a $400+ million deal with big pharma Takeda for its lead asset, Cx601, which should be approved in Europe before YE2017

TiGenix Announces Final Equity Payment For Cardiac Platform Acquisition

2017-06-12 devicespace
Leuven (BELGIUM) - June 12, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces a €5 million milestone payment in new TiGenix shares to Genetrix in relation to the cardiac platform acquisition that took place in July 2015.

TiGenix Announces Final Equity Payment For Cardiac Platform Acquisition

2017-06-12 devicespace
Leuven (BELGIUM) - June 12, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces a €5 million milestone payment in new TiGenix shares to Genetrix in relation to the cardiac platform acquisition that took place in July 2015.

TiGenix to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on March 23, 2017

2017-03-22 prnewswire
Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event

Pipeline of Congestive Heart Failure Market Review Research for H1 2017 - Reports and Reports

2017-03-22 prnewswire
ReportsnReports.com adds "Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017" to its store providing comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

MIDEAST STOCKS-Depressed oil prices may continue to weigh on Gulf

2017-03-13 reuters
DUBAI, March 13 A further slide in oil prices may weigh on Gulf stock markets on Monday with Saudi Arabia's index possibly underperforming its peers becuase of that market's large petrochemical sector.

BRIEF-Ipsen says MHRA has approved a new indication for Decapeptyl

2017-03-13 reuters
* Ipsen announces mhra1 approval of new indication for Decapeptyl® for the treatment of pre-menopausal women with early stage breast cancer

BRIEF-Tigenix NV announces top-line one-year results from Caremi clinical trial

2017-03-13 reuters
* Tigenix NV - announced top-line one-year results from Caremi clinical trial, an exploratory phase I/II study of Allocscs in acute myocardial infarction

BRIEF-Tigenix receives positive feedback from FDA on Cx601 global phase III trial protocol

2017-03-07 reuters
* Tigenix NV - received positive feedback from U.S. FDA on an improved protocol for its global phase III trial for treatment of complex perianal fistulas